2024
Patterns of loco-regional progression and patient outcomes after definitive-dose radiation therapy for anaplastic thyroid cancer
Bronk J, Augustyn A, Mohamed A, Fuller C, Garden A, Moreno A, Lee A, Morrison W, Phan J, Reddy J, Rosenthal D, Spiotto M, Frank S, Dadu R, Busaidy N, Zafereo M, Wang J, Maniakas A, Ferrarotto R, Iyer P, Cabanillas M, Gunn G. Patterns of loco-regional progression and patient outcomes after definitive-dose radiation therapy for anaplastic thyroid cancer. Radiotherapy And Oncology 2024, 202: 110602. PMID: 39489425, PMCID: PMC11720968, DOI: 10.1016/j.radonc.2024.110602.Peer-Reviewed Original ResearchIntensity modulated radiation therapyLoco-regional progressionAnaplastic thyroid cancerTarget volumeConcurrent chemotherapyRadiation therapyThyroid cancerHigh dosesAreas of gross diseaseMedian progression free survivalMedian IMRT doseGross tumor volumeMedian overall survivalProgression free survivalNeo-adjuvant strategiesDeformable image registrationIntensive treatment scheduleLevels II-VDiagnostic CTsIMRT dosePlanning CTsGross diseaseLocoregional diseaseUnresectable diseaseFree survivalHypoxia-Directed Treatment of Human Papillomavirus–Related Oropharyngeal Carcinoma
Lee N, Sherman E, Schöder H, Wray R, Boyle J, Singh B, Grkovski M, Paudyal R, Cunningham L, Zhang Z, Hatzoglou V, Katabi N, Diplas B, Han J, Imber B, Pham K, Yu Y, Zakeri K, McBride S, Kang J, Tsai C, Chen L, Gelblum D, Shah J, Ganly I, Cohen M, Cracchiolo J, Morris L, Dunn L, Michel L, Fetten J, Kripani A, Pfister D, Ho A, Shukla-Dave A, Humm J, Powell S, Li B, Reis-Filho J, Diaz L, Wong R, Riaz N. Hypoxia-Directed Treatment of Human Papillomavirus–Related Oropharyngeal Carcinoma. Journal Of Clinical Oncology 2024, 42: 940-950. PMID: 38241600, PMCID: PMC10927322, DOI: 10.1200/jco.23.01308.Peer-Reviewed Original ResearchConceptsProgression-free survivalCurative-intent chemoradiotherapyLocoregional controlOropharyngeal carcinomaOverall survivalGrade 3Adverse eventsTumor hypoxiaHuman papillomavirus (HPV)-related oropharyngeal carcinomasHPV-related oropharyngeal carcinomaMedian follow-up timeHypoxic tumorsSurgical removal of diseaseAcute grade 3Late grade 3HPV-related carcinomasPhase II studyFollow-up timeMeasure tumor hypoxiaRemoval of diseaseDefinitive chemoradiotherapyStandard chemoradiotherapyGross diseaseLate dysphagiaOS rates
2022
Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy
Youssef I, Yoon J, Mohamed N, Zakeri K, Press R, Yu Y, Kang J, Wong R, Tuttle R, Shaha A, Sherman E, Lee N. Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy. International Journal Of Particle Therapy 2022, 9: 20-30. PMID: 36060412, PMCID: PMC9415751, DOI: 10.14338/ijpt-22-00005.1.Peer-Reviewed Original ResearchPercent of patientsLocal-regional recurrenceThyroid cancerRadiation therapyGross diseaseOverall survivalPercutaneous endoscopic gastrostomy tubeProton therapyProton beam radiation therapyAcute grade 3Central neck compartmentFavorable therapeutic ratioIntensity-modulated radiation therapyBeam radiation therapyProton beam therapyConcurrent chemotherapyPalliative radiationUnresectable diseaseAdjuvant radiationDefinitive radiationT4 diseaseMetastatic diseaseNeck compartmentRegional recurrenceUpper mediastinumEvaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus–Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy
Tsai CJ, McBride SM, Riaz N, Kang JJ, Spielsinger DJ, Waldenberg T, Gelblum D, Yu Y, Chen LC, Zakeri K, Wong RJ, Dunn L, Pfister DG, Sherman EJ, Lee NY. Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus–Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy. JAMA Oncology 2022, 8: 364-372. PMID: 35050342, PMCID: PMC8778604, DOI: 10.1001/jamaoncol.2021.6416.Peer-Reviewed Original ResearchConceptsDistant metastasis-free survivalProgression-free survivalMetastasis-free survivalOropharyngeal carcinomaConcurrent chemoradiotherapyDe-escalation strategiesRadiotherapy doseTotal doseSubclinical regionsLocoregional controlGross diseaseCohort studyOverall survivalClinical outcomesHuman Papillomavirus–Associated Oropharyngeal CarcinomaHigh-dose cisplatin therapyHPV-positive oropharyngeal carcinomaTarget volumeBilateral level IBGy of radiotherapyPrimary concurrent chemoradiotherapyRetrospective cohort studyFavorable clinical outcomeAmerican Joint CommitteeLong-term follow
2021
Dose and Volume De-Escalation for Elective Nodal Regions in Patients With Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer (OPC) Undergoing Curative-Intent Concurrent Chemoradiation (CCRT)
Tsai C, McBride S, Riaz N, Kang J, Spielsinger D, Waldenberg T, Yu Y, Chen L, Zakeri K, Wong R, Dunn L, Sherman E, Lee N. Dose and Volume De-Escalation for Elective Nodal Regions in Patients With Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer (OPC) Undergoing Curative-Intent Concurrent Chemoradiation (CCRT). International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s142-s143. DOI: 10.1016/j.ijrobp.2021.07.321.Peer-Reviewed Original ResearchConcurrent chemoradiationDe-escalation strategiesOropharyngeal cancerGross diseaseNodal recurrenceDisease recurrenceOPC patientsLevel IbHPV-positive OPC patientsLocoregional recurrence-free survivalElective nodal regionsFavorable locoregional controlFeeding tube dependenceHigh-dose cisplatinPositive oropharyngeal cancerPrimary concurrent chemoradiationRecurrence-free survivalNode-positive neckFeeding tube placementLong-term resultsNode-negative neckDe-escalation approachMATERIAL/METHODSHigh control ratesRadiation treatment plans
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply